{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-111704","form_type":"8-K","ticker":"DMAA","cik":"0002028614","company_name":"Drugs Made In America Acquisition Corp.","filed_at":"2025-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.379660+00:00","generated_at":"2026-05-16T18:55:25.220121+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"CFO Glenn Worman resigns; Saleem Elmasri appointed as CFO of Drugs Made In America Acquisition Corp.","bullets":["Glenn Worman resigned as CFO and principal financial & accounting officer on Oct 8, 2025; no disagreement cited.","Saleem Elmasri appointed CFO effective Nov 17, 2025; will serve via Titan Advisory Services LLC.","Elmasri receives $42,000/year ($3,500/month) consulting fee and 100,000 ordinary shares upon engagement.","Elmasri is a CPA with 20 years experience, previously at PwC and as managing partner at Titan Advisory."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-111704","json":"https://secwatch.observer/filing/0001213900-25-111704.json","markdown":"https://secwatch.observer/filing/0001213900-25-111704.md","text":"https://secwatch.observer/filing/0001213900-25-111704.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2028614/000121390025111704/0001213900-25-111704-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2028614/000121390025111704/ea0265998-8k_drugs.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:55:25.220121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}